Dopamine dysfunction is a mainstay of theories aimed to explain the neurobiological correlates of schizophrenia symptoms, particularly positive symptoms such as delusions and passivity phenomena. Based on studies revealing dopamine dysfunction in addiction research, it has been suggested that phasic or chaotic firing of dopaminergic neurons projecting to the (ventral) striatum attribute salience to otherwise irrelevant stimuli and thus contribute to delusional mood and delusion formation. Indeed, several neuroimaging studies revealed that neuronal encoding of usually irrelevant versus relevant stimuli is blunted in unmedicated schizophrenia patients, suggesting that some stimuli that are irrelevant for healthy controls acquire increased salience for psychotic patients. However, salience attribution per se may not suffice to explain anxieties and feelings of threat that often accompany paranoid ideation. Here, we suggest that beyond ventral striatal dysfunction, dopaminergic dysregulation in limbic areas such as the amygdala in interaction with prefrontal and temporal cortex may contribute to the formation of delusions and negative symptoms. Neuroleptic medication, on the other hand, appears to interfere with anticipation of reward in the ventral striatum and can thus contribute to secondary negative symptoms such as apathy and avolition.

Keywords:
Delusions, Brain imaging, Schizophrenia, Dopamine, Functional and structural disconnection
1.
Jaspers K: Allgemeine Psychopathologie, 8 Aufl. Berlin, Springer, 1965.
2.
Heinz A: Dopaminergic dysfunction in alcoholism and schizophrenia –psychopathological and behavioral correlates. Eur Psychiatry 2002;17:9–16.
3.
Murray RM, Lewis SW: Is schizophrenia a neurodevelopmental disorder? BMJ (Clin Res Ed) 1987;295:681–682.
4.
Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660–669.
5.
Heinz A, Weinberger DR: Schizophrenia: The neurodevelopmental hypothesis. Current Concepts in Psychiatry (Psychiatrie der Gegenwart). Berlin, Springer, 2000, pp 89–104.
6.
Carlsson A, Waters N, Carlsson ML: Neurotransmitter interactions in schizophrenia – therapeutic implications. Biol Psychiatry 1999;46:1388–1395.
7.
Heinz A, Saunders RC, Kolachana BS, Jones DW, Gorey JG, Bachevalier J, Weinberger DR: Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage. Synapse 1999;32:71–79.
8.
Shenton ME, Dickey CC, Frumin M, McCarley RW: A review of MRI findings in schizophrenia. Schizophr Res 2001;49:1–52.
9.
Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS: Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992;160:179–186.
10.
Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, Cleghorn JM: Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 1993;11:47–54.
11.
Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U: Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 1997;349:1735–1739.
12.
Puri BK, Lekh SK, Nijran KS, Bagary MS, Richardson AJ: SPECT neuroimaging in schizophrenia with religious delusions. Int J Psychophysiol 2001;40:143–148.
13.
Kohno T, Shiga T, Kusumi I, Matsuyama T, Kageyama H, Katoh C, Koyama T, Tamaki N: Left temporal perfusion associated with suspiciousness score on the Brief Psychiatric Rating Scale in schizophrenia. Psychiatry Res 2006;147:163–171.
14.
Ragland JD, Valdez JN, Loughead J, Gur RC, Gur RE: Functional magnetic resonance imaging of internal source monitoring in schizophrenia: recognition with and without recollection. Schizophr Res 2006;87:160–171.
15.
Russell TA, Reynaud E, Kucharska-Pietura K, Ecker C, Benson PJ, Zelaya F, Giampietro V, Brammer M, David A, Phillips ML: Neural responses to dynamic expressions of fear in schizophrenia. Neuropsychologia 2007;45:107–123.
16.
Kwon JS, McCarley RW, Hirayasu Y, Anderson JE, Fischer IA, Kikinis R, Jolesz FA, Shenton ME: Left planum temporale volume reduction in schizophrenia. Arch Gen Psychiatry 1999;56:142–148.
17.
Szeszko PR, Bilder RM, Lencz T, Pollack S, Alvir JM, Ashtari M, Wu H, Lieberman JA: Investigation of frontal lobe subregions in first-episode schizophrenia. Psychiatry Res 1999;90:1–15.
18.
Nestor PG, Onitsuka T, Gurrera RJ, Niznikiewicz M, Frumin M, Shenton ME, McCarley RW: Dissociable contributions of MRI volume reductions of superior temporal and fusiform gyri to symptoms and neuropsychology in schizophrenia. Schizophr Res 2007;91:103–106.
19.
Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998;155:1711–1717.
20.
Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V: Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011;68:128–137.
21.
Rao NP, Kalmady S, Arasappa R, Venkatasubramanian G: Clinical correlates of thalamus volume deficits in anti-psychotic-naive schizophrenia patients: a 3-Tesla MRI study. Indian J Psychiatry 2010;52:229–235.
22.
Takahashi T, Zhou SY, Nakamura K, Tanino R, Furuichi A, Kido M, Kawasaki Y, Noguchi K, Seto H, Kurachi M, Suzuki M: Longitudinal volume changes of the pituitary gland in patients with schizotypal disorder and first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:177–183.
23.
Whitford TJ, Farrow TF, Williams LM, Gomes L, Brennan J, Harris AW: Delusions and dorso-medial frontal cortex volume in first-episode schizophrenia: a voxel-based morphometry study. Psychiatry Res 2009;172:175–179.
24.
Basser PJ, Mattiello J, LeBihan D: MR diffusion tensor spectroscopy and imaging. Biophys J 1994;66:259–267.
25.
Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, Niznikiewicz M, Connor EE, Levitt JJ, Frumin M, Kikinis R, Jolesz FA, McCarley RW, Shenton ME: DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage 2005;26:1109–1118.
26.
Knobel A, Heinz A, Voss M: Imaging the deluded brain. Eur Arch Psychiatry Clin Neurosci 2008;258(suppl 5):76–80.
27.
Skelly LR, Calhoun V, Meda SA, Kim J, Mathalon DH, Pearlson GD: Diffusion tensor imaging in schizophrenia: relationship to symptoms. Schizophr Res 2008;98:157–162.
28.
Fujiwara H, Namiki C, Hirao K, Miyata J, Shimizu M, Fukuyama H, Sawamoto N, Hayashi T, Murai T: Anterior and posterior cingulum abnormalities and their association with psychopathology in schizophrenia: a diffusion tensor imaging study. Schizophr Res 2007;95:215–222.
29.
Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM: Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 2008;33:976–984.
30.
Kalus P, Buri C, Slotboom J, Gralla J, Remonda L, Dierks T, Strik WK, Schroth G, Kiefer C: Volumetry and diffusion tensor imaging of hippocampal subregions in schizophrenia. Neuroreport 2004;15:867–871.
31.
Kalus P, Slotboom J, Gallinat J, Wiest R, Ozdoba C, Federspiel A, Strik WK, Buri C, Schroth G, Kiefer C: The amygdala in schizophrenia: a trimodal magnetic resonance imaging study. Neurosci Lett 2005;375:151–156.
32.
Chan WY, Yang GL, Chia MY, Lau IY, Sitoh YY, Nowinski WL, Sim K: White matter abnormalities in first-episode schizophrenia: a combined structural MRI and DTI study. Schizophr Res 2010;119:52–60.
33.
Zhou Y, Shu N, Liu Y, Song M, Hao Y, Liu H, Yu C, Liu Z, Jiang T: Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia. Schizophr Res 2008;100:120–132.
34.
Kienast T, Heinz A: Dopamine and the diseased brain. CNS Neurol Disord Drug Targets 2006;5:109–131.
35.
Schultz W, Dayan P, Montague PR: A neural substrate of prediction and reward. Science 1997;275:1593–1599.
36.
Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247–291.
37.
Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13–23.
38.
Conrad K: Die beginnende Schizophrenie. Stuttgart, Thieme, 1958.
39.
Selten JP, Cantor-Graae E: Social defeat: risk factor for schizophrenia? Br J Psychiatry 2005;187:101–102.
40.
Knutson B, Fong GW, Adams CM, Varner JL, Hommer D: Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 2001;12:3683–3687.
41.
Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A: Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006;29:409–416.
42.
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000;97:8104–8109.
43.
Romaniuk L, Honey GD, King JR, Whalley HC, McIntosh AM, Levita L, Hughes M, Johnstone EC, Day M, Lawrie SM, Hall J: Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia. Arch Gen Psychiatry 2010;67:1246–1254.
44.
Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M: Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000;48:627–640.
45.
Corlett PR, Honey GD, Aitken MR, Dickinson A, Shanks DR, Absalom AR, Lee M, Pomarol-Clotet E, Murray GK, McKenna PJ, Robbins TW, Bullmore ET, Fletcher PC: Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry 2006;63:611–621.
46.
Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC: Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 2007;130:2387–2400.
47.
Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A: Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006;187:222–228.
48.
Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A: Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008;196:673–684.
49.
Schlagenhauf F, Sterzer P, Schmack K, Ballmaier M, Rapp M, Wrase J, Juckel G, Gallinat J, Heinz A: Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 2009;65:1032–1039.
50.
Phan KL, Wager TD, Taylor SF, Liberzon I: Functional neuroimaging studies of human emotions. CNS Spectr 2004;9:258–266.
51.
Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, Smolka MN, Grunder G, Cumming P, Kumakura Y, Bartenstein P, Dolan RJ, Heinz A: Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci 2008;11:1381–1382.
52.
Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Grunder G: Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 2007;27:8080–8087.
53.
Coltheart M: Cognitive neuropsychiatry and delusional belief. Q J Exp Psychol (Colchester) 2007;60:1041–1062.
54.
Coltheart M: Delusional belief. Annu Rev Psychol 2011;57:72–76.
55.
McKay R, Langdon R, Coltheart M: Models of misbelief: integrating motivational and deficit theories of delusions. Conscious Cogn 2007;16:932–941.
56.
Corlett PR, Taylor JR, Wang XJ, Fletcher PC, Krystal JH: Toward a neurobiology of delusions. Prog Neurobiol 2010;92:345–369.
57.
Gottesman L, Chapman LJ: Syllogistic reasoning errors in schizophrenia. J Consult Psychol 1960;24:250–255.
58.
Murray GK: The emerging biology of delusions. Psychol Med 2011;41:7–13.
59.
Fletcher PC, Frith CD: Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 2009;10:48–58.
60.
Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC: Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry 2008;13:239, 267–276.
61.
Blackwood NJ, Howard RJ, Bentall RP, Murray RM: Cognitive neuropsychiatric models of persecutory delusions. Am J Psychiatry 2001;158:527–539.
62.
Bentall RP, Kaney S: Content specific information processing and persecutory delusions: an investigation using the emotional Stroop test. Br J Med Psychol 1989;62:355–364.
63.
Blackwood NJ, Bentall RP, Ffytche DH, Simmons A, Murray RM, Howard RJ: Persecutory delusions and the determination of self-relevance: an fMRI investigation. Psychol Med 2004;34:591–596.
64.
Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, Skerrett D, Phillips ML, David AS, Peduto A, Gordon E: Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry 2004;161:480–489.
65.
Garety PA, Hemsley DR, Wessely S: Reasoning in deluded schizophrenic and paranoid patients. Biases in performance on a probabilistic inference task. J Nerv Ment Dis 1991;179:194–201.
66.
Moritz S, Laudan A: Attention bias for paranoia-relevant visual stimuli in schizophrenia. Cogn Neuropsychiatry 2007;12:381–390.
67.
Heinz A, Schlagenhauf F: Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010;36:472–485.
68.
Makris N, Seidman LJ, Ahern T, Kennedy DN, Caviness VS, Tsuang MT, Goldstein JM: White matter volume abnormalities and associations with symptomatology in schizophrenia. Psychiatry Res 2010;183:21–29.
69.
Mitelman SA, Torosjan Y, Newmark RE, Schneiderman JS, Chu KW, Brickman AM, Haznedar MM, Hazlett EA, Tang CY, Shihabuddin L, Buchsbaum MS: Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: a diffusion tensor imaging survey. Schizophr Res 2007;92:211–224.
70.
Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S: The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 2008;33:473–479.
71.
Walter H, Kammerer H, Frasch K, Spitzer M, Abler B: Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (Berl) 2009;206:121–132.
72.
Rotarska-Jagiela A, van dV, V, Oertel-Knochel V, Uhlhaas PJ, Vogeley K, Linden DE: Resting-state functional network correlates of psychotic symptoms in schizophrenia. Schizophr Res 2010;117:21–30.
73.
Gradin VB, Kumar P, Waiter G, Ahearn T, Stickle C, Milders M, Reid I, Hall J, Steele JD: Expected value and prediction error abnormalities in depression and schizophrenia. Brain 2011;134:1751–1764.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.